Los Angeles Capital Management LLC Purchases New Stake in Keros Therapeutics, Inc. $KROS

Los Angeles Capital Management LLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,709 shares of the company’s stock, valued at approximately $557,000. Los Angeles Capital Management LLC owned approximately 0.10% of Keros Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently made changes to their positions in KROS. Vanguard Group Inc. increased its holdings in shares of Keros Therapeutics by 31.1% in the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock valued at $26,151,000 after purchasing an additional 609,212 shares in the last quarter. ADAR1 Capital Management LLC grew its position in Keros Therapeutics by 6,294.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock worth $15,147,000 after buying an additional 1,463,215 shares during the period. Federated Hermes Inc. grew its position in Keros Therapeutics by 882.3% during the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock worth $12,474,000 after buying an additional 1,099,519 shares during the period. Goldman Sachs Group Inc. increased its holdings in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after buying an additional 205,022 shares in the last quarter. Finally, DRW Securities LLC acquired a new stake in shares of Keros Therapeutics during the 1st quarter valued at approximately $4,737,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Keros Therapeutics

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of Keros Therapeutics stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $84,975,125.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $95,659,436.00. Additional details regarding this sale are available in the official SEC disclosure. 20.60% of the stock is currently owned by insiders.

Keros Therapeutics Trading Down 0.2%

Keros Therapeutics stock opened at $17.26 on Friday. The stock has a 50-day moving average price of $15.66 and a 200 day moving average price of $14.73. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $72.37. The stock has a market cap of $525.91 million, a PE ratio of 11.21, a P/E/G ratio of 0.38 and a beta of 1.12.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.93. The company had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The firm’s revenue for the quarter was up 3585.6% compared to the same quarter last year. During the same period last year, the company earned ($1.41) EPS. On average, equities analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KROS. Weiss Ratings restated a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Oppenheimer reissued an “outperform” rating and issued a $27.00 target price (up previously from $23.00) on shares of Keros Therapeutics in a report on Wednesday. Wells Fargo & Company cut their price target on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday. Wedbush boosted their price objective on shares of Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. Finally, Zacks Research upgraded shares of Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.22.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.